Monoclonal antibody developer Cytogen of Princeton, NJ, has received the Food and Drug Administration's go-ahead to market its Quadramet cancer therapy agent for relieving pain in patients whose cancer has spread to the bone. Quadramet is indicated in
Monoclonal antibody developer Cytogen of Princeton, NJ, has received the Food and Drug Administration's go-ahead to market its Quadramet cancer therapy agent for relieving pain in patients whose cancer has spread to the bone. Quadramet is indicated in patients with osteoblastic metastatic bone lesions, which can be caused by prostate, bone, or breast cancer.
Quadramet will be marketed in the U.S., Canada, and Latin America by Du Pont Merck Radiopharmaceuticals, with shipments scheduled to begin this quarter. The news of the FDA's action caused Cytogen's stock to surge 56, or 11%, to end at $5.81 on March 31, the day the news was announced.
In other Cytogen news, the company said that it has begun phase I clinical trials investigating the use of Quadramet for treating patients with refractory rheumatoid arthritis. The study will be conducted at the University of Iowa and will enroll about 30 patients.
Another Cytogen technology, prostate specific membrane antigen (PSMA), has shown promise in preliminary research as a possible vaccine to fight prostate cancer. Cytogen has licensed PSMA technology to a company called Prostagen, which is researching the use of immunotherapy for advanced prostate cancer.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.